昆明妇科医院 台俪昆明打胎便宜,昆明1个月做打胎多钱,昆明有那几家较好的流产医院,昆明有什么好的流产医院,昆明怀孕多少天可以打胎,昆明台俪妇科医院的售后服务电话,昆明做人流需要住院吗

BAIKONUR, Kazakhstan, Nov. 9 (Xinhua) -- Russia's Phobos-Grunt probe and China's Yinghuo-1 satellite were launched from the Baikonur cosmodrome in Kazakhstan on a Zenit-2SB rocket at 00:16 am Moscow time Wednesday (2016 GMT Tuesday).The main aim of the Phobos-Grunt unmanned mission is to bring back the first ever soil sample from Phobos, the larger of Mars' two moons.Russia had spent about 5 billion rubles (about 161 million U.S. dollars) preparing for the three-year mission, which would include drilling Phobos' surface and returning 200 grams of soil back to Earth, according to Russian state space agency Roscosmos.The mission would also collect bacteria samples for two Russian and one U.S. biological experiments.In the meantime, China's first Mars probe Yinghuo will go into orbit around Mars and observe the planet itself.Phobos-Grunt is planned to reach Mars in 2012, then deploy its lander for Phobos in 2013 and return the soil sample back to Earth in August 2014.The Chinese probe, which would not land on Mars nor return to the Earth, is expected stay permanently in the space and communicate with the ground control directly via satellites.The Chinese probe is 75 cm long, 75 cm wide and 60 cm high. It weighs 115 kilograms and was designed for a two-year life to discover why water disappeared from Mars and shed light on other environmental changes on the planet.Victor Khartov, chief designer and director general of Lavochkin Research & Production Association, told Xinhua that the three-year mission is highly complicated."It consists of eight sub-missions: launch, travel to Mars vicinities, separation with the Chinese probe YH-1, landing on Phobos, soil collection, launch from Phobos, way back to the Earth, and final landing. Failure of any one of them could doom the entire project," he said.The launch of Phobos-Grunt and Yinghuo-1, originally scheduled for October 2009 on a Russian carrier rocket, has been postponed until 2011 due to "technical reasons" on the Russian side.

LOS ANGELES, Dec. 21 (Xinhua) -- The late Apple co-founder Steve Jobs will be honored posthumously with a Grammy award for his contributions to music technology, The Recording Academy announced on Wednesday.Jobs, who passed away Oct. 5 of pancreatic cancer, will receive a Trustees Award for helping create products "that transformed the way we consume music, TV, movies and books," the academy said in a prepared statement.The Apple Computer Inc. first received a Technical Grammy Award in 2002, for contributions of outstanding technical significance to the recording field, the academy said.Along with Jobs, bandleader and composer Dave Bartholomew, recording engineer Rudy Van Gelder will also receive the award.The academy also picked the Allman Brothers, Glen Campbell, Diana Ross and Brazilian pianist/singer/guitarist Antonio Carlos Jobim as recipients of Lifetime Achievement Awards. Jobim was known for composing "The Girl from Ipanema," a worldwide hit in the mid-1960s which won a Grammy for Record of the Year in 1965.Other artists, including trumpeter Wayne Jackson, saxophonist Andrew Love of the Memphis Horns,country legend George Jones,and the late Gil Scott-Heron were also named as recipients.German sound-technology firm Celemony and the late audio engineer Roger Nichols, who worked with artists including Ross, Placido Domingo, James Taylor and Stevie Wonder, were recognized with Grammy Technical Awards."This year's honorees offer a variety of brilliance, contributions and lasting impressions on our culture," said President/CEO of The Recording Academy Neil Portnow. "It is an honor to recognize such a diverse group of individuals whose talents and achievements have had an indelible impact on our industry."The honorees will be formally acknowledged during the 54th Annual Grammy Awards telecast at Staples Center in downtown Los Angeles on Feb. 12, 2012.

SAN FRANCISCO, Oct. 13 (Xinhua) -- The Internet search giant Google on Thursday released its third fiscal quarter earnings report, posting strong numbers that beat analysts' estimates.The Mountain View, California-based company reported revenue of 9.72 billion U.S. dollars for the quarter ending Sept. 30, 2011, an increase of 33 percent on a year-on-year basis.Google reported a profit of 2.73 billion dollars, compared to 2. 17 billion dollars in the same period last year. The earning per share, excluding certain items, is 9.72 dollars, topping the average estimate of 8.74 dollars per share polled by Thomson Reuters."We had a great quarter," said Google co-founder and Chief Executive Officer Larry Page in a statement. "Google+ is now open to everyone and we just passed the 40 million user mark. People are flocking into Google+ at an incredible rate and we are just getting started."Many analysts took the third quarter to examine the company's progress towards expanding its core business beyond advertising which accounted for 96 percent of its revenue last year. In the past quarter, Google made major investments in several key businesses, such as social networking and mobile.In August, Google announced a 12.5-billion-dollar acquisition of Motorola Mobility, a move widely seen to get Motorola's patent portfolio to protect its Android software against a growing number of infringement lawsuits by rival mobile platforms. The deal is expected to close later this year or early next year.Since its late-June launch, the Google+ social network has been receiving a good response, posing to shake up the social networking space dominated by Facebook.In September, Google also officially launched Google Wallet, a mobile payment allowing users to pay by tapping an Android smartphone against a compatible card reader.

WASHINGTON, Dec. 21 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Wednesday approved Isentress for the treatment of HIV-1 infection for children and adolescents.The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program."Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. As the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.A single, multi-center clinical trial of 96 children and adolescents aged 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.According to the FDA, the most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash.

SAN FRANCISCO, Nov. 3 (Xinhua) -- Computer chipmaker Advanced Micro Devices Inc. (AMD) on Thursday said it plans to cut its global workforce by about 10 percent in a move to reduce operational costs.The layoff will occur across all functions globally and is expected to be substantially completed by the end of the first quarter of 2012, the company said.The cuts will amount to about 1,400 jobs, according to estimates by analysts.Combined with implementing efficiencies across the company's operations, AMD expected that the workforce reduction will result in operational savings of more than 200 million U.S. dollars in 2012."Reducing our cost structure and focusing our global workforce on key growth opportunities will strengthen AMD's competitiveness and allow us to aggressively pursue a balanced set of strategic activities designed to accelerate future growth," Rory Read, AMD's chief executive officer, said in a statement.As the world's second largest maker of processors for computers, AMD has been suffering from the slowdown of global PC market and is seen as slow to move into new mobile device market.The operational savings will help accelerate the company's future growth in lower power, emerging markets and in the cloud computing field, AMD said.